While chemotherapy drugs kill rapidly dividing cells and exhibit high toxicities, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are designed to specifically target receptors on cancer cells, such as the epidermal growth factor receptor (EGFR) and several oncogenic receptors such as tyrosine kinase (RTK) [2,3,4]. The gene discussed is EGFR; the disease is cancer.